News

Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Submitted NDA for Anaphylm (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of An ...
The Manila Times12h
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...